St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, has announced positive results for the 23 and 25 mm Portico™ Transcatheter Aortic Heart Valves in the Portico Transfemoral CE Mark Trial (Portico TF CE Trial). Patients enrolled in the study experienced a significant improvement in valve function at 30 days. The preliminary findings indicate exceptional hemodynamic performance (the ability to maximize blood flow) and improvement in the severity of heart failure symptoms as measured by the New York Heart Association (NYHA) Functional Classification System...
No comments:
Post a Comment